GALE Study (Protocol number: APL2-GA-305)

A 36 month, phase 3 open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy secondary to age-related macular degeneration.

ClinicalTrials.gov Identifier: NCT04770545

Principal Investigator: Dr Fred Chen

For further information about this study, you may visit the Clinical Trial Registry:

Or contact the Lions Eye Institute Clinical Trials Office telephone (08) 9381 0750 or email lionsvisiontrials@lei.org.au.

Need any help?

If you would like to know more about us, or want to make an appointment, please don’t hesitate to get in touch.

Request an appointment